Quality of Life of Patients with Hormone Refractory Prostate Cancer After Gene Therapy

摘要: Bone metastasis in cancer patients is observed with high clinical frequency and associated not only pain but also pathological fractures, restriction of daily activities, other skeletal-related events (SRE). It therefore an issue a very decisive effect on subsequent quality life (QOL) (Chow & Bottomley, 2009). The development new therapies for bone recent years has allowed progress from the use narcotic formulations, typical which are conventional opioid drugs, to treatments focused ‘bone health’ apply multidisciplinary approach combining instance high-strength bisphosphonate preparations radionuclide therapy (Satoh et al., In prostate breast cancer, have incidence metastasis, there many cases where survival number can be expected even at stage illness this kind present, therapeutic strategy needs take account QOL. Each year thousands men diagnosed cancer; it estimated that about 192,280 will disease 2009 (American Cancer Society, 2008). advanced disease, androgen-deprivation remains best treatment. After median response 12 24 months, develop progressive hormone-refractory (HRPC) (Carroll 2002, Chodak 2002). Therefore, advantage greater antitumor effects necessary. Gene good candidate among therapies. phase I trial combination osteocalcin promoter-driven herpessimplex-virus thymidine kinase (Ad-OC-TK) valacyclovir (VAL) treatment HRPC been conducted previously University Virginia (Kubo 2003). Between August 2003 March 2006, I/II dose-escalating intratumoral injections Ad-OC-TK was performed 6 order assess potential toxicity Kobe Hospital (Hinata Shirakawa 2007). oncological trials, tumor volume serum levels markers frequently used as primary indices. However, recently, assessment QOL become important index. Since generally